The Worldwide Drug Discovery Services Industry is Expected to Reach $31.4 Billion by 2026 – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Drug Discovery Services Market by Process (Target Selection, Validation, Hit-to-lead), Type (Chemistry, Biology), Drug Type (Small molecules, biologics), Therapeutic Area (Oncology, Neurology) End User (Pharma, Biotech) – Global Forecast to 2026” report has been added to ResearchAndMarkets.com’s offering.

The global Drug discovery services market is projected to reach USD 31.4 billion by 2026 from USD 16.1 billion in 2021, at a CAGR of 14.3% during the forecast period of 2021 to 2026.

Growing R&D expenditure in the pharmaceutical & biopharmaceutical industry, increasing demand for outsourcing analytical testing services, initiatives for research on rare diseases and orphan drugs, and the high cost of in-house drug development are creating new revenue pockets in the drug discovery services market.

The chemistry services segment accounted for the largest share of the type segment in the drug discovery services market in 2020

Based on type, the drug discovery services market is segmented into chemistry and biology services. The chemistry services segment commanded the largest share of this market in 2020. Growth in this market segment is largely due to the widespread application of chemistry in various early drug development phases to deliver robust candidates. The extensive usage of chemistry in academics, biotechnology companies, and large pharmaceutical companies also supports market growth.

The Hit-to-lead identification segment accounted for the largest share of the process segment in the drug discovery services market in 2020

Based on process, the drug discovery services market is broadly classified into target selection, target validation, hit-to-lead identification, lead optimization, and candidate validation. Hit-to-lead identification segment accounted for the largest share of the drug discovery services market in 2020. Due to its vital role in drug discovery, hit-to-lead identification is the most revenue-generating process, and currently, many CROs are offering these services to pharmaceutical companies.

The Oncology segment accounted for the largest share of the therapeutic area segment in the drug discovery services market in 2020

Based on therapeutic area, the drug discovery services market is segmented into oncology, infectious and immune system diseases, neurology, digestive system diseases, cardiovascular diseases, and other therapeutic areas. Oncology is the largest segment in this market owing to the high incidence of cancer, a growing number of research studies on cancer therapeutics, and a company focus on bringing innovative cancer drugs into the market.

Asia Pacific: The fastest-growing region in the drug discovery services market

The drug discovery services market is segmented into North America, Europe, Asia Pacific, Latin America (LATAM) and Middle East and Africa (MEA). The APAC is estimated to record the highest CAGR during the forecast period. The vast patient population, emerging middle-class, rising government spending, and therapeutic area expertise are the major growth drivers for the pharmaceutical industry in the region. Global pharmaceutical firms are increasingly moving to Asia to tap into its thriving market and lower their production costs by shifting manufacturing to the region.

Market Dynamics

Drivers

• Growing R&D Expenditure in the Pharma & Biopharma Industry
• Increasing Demand for Outsourcing Analytical Testing
• Initiatives for Research on Rare Diseases and Orphan Drugs
• High Cost of In-House Drug Development

Restraints

• Stringent Regulations Governing Drug Discovery and Animal Usage

Opportunities

• Growth in Drugs and Biologics Market Despite COVID-19 Pandemic
• Rising Demand for Specialized Testing Services Among End-users
• Patent Expiry
• High Growth Prospects in Emerging Markets

Challenges

• Shortage of Skilled Personnel

Trends

• Shift in Drug Discovery Services due to Growing Adoption of Ai-Based Tools
• Increased Outsourcing to Emerging Asian Economies
• Cro Industry Consolidation
• Integrated End-To-End R&D Service Solution

Companies Mentioned

• Laboratory Corporation of America Holdings
• Charles River Laboratories International, Inc.
• Wuxi Apptec
• Thermo Fisher Scientific
• Pharmaron Beijing Co., Ltd.
• Evotec Se
• Eurofins Scientific Se
• Pharmaceutical Product Development, Inc.
• Piramal Enterprises Limited
• Syngene International Limited
• Curia Global Inc.
• Genscript Biotech Corporation
• Jubilant Pharmova Limited
• Frontage Holdings Corporation
• Shanghai Medicilon Inc.
• Dr. Reddy’s Laboratories Ltd. (Aurigene Discovery Technologies)
• Selvita S.A. (Formerly Selvita Cro S.A.)
• Viva Biotech (Shanghai) Ltd.
• Tcg Lifesciences Pvt Ltd.
• Shanghai Chempartner Co., Ltd.
• Domainex Ltd.
• Nuvisan Pharma Holding GmbH
• Dalton Pharma Services
• Aragen Life Sciences Pvt. Ltd. (Formerly Gvk Biosciences Pvt. Ltd.)
• Promega Corporation

For more information about this report visit https://www.researchandmarkets.com/r/a6t17u

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

[email protected]

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900